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BACKGROUND: Pseudoxanthoma elasticum (PXE) is thought to be a metabolic
disorder resulting from mutations in the gene encoding the cellular transporter,
ABCC6, which is primarily expressed in liver and kidney. We encountered 3 patients
who developed clinical and histopathological evidence of PXE after liver
transplantation, suggesting that PXE could have been acquired from the
transplanted organ. OBJECTIVE: We sought to delineate the clinical features and
screen each patient and samples of donor liver for mutations in the ABCC6 gene.
METHODS: Each patient underwent full clinical examination, skin biopsy, and
ophthalmologic examination, and whole genome sequencing using standard
techniques. Fixed samples of donor liver tissue were available for mutation analysis
in two patients and of donor kidney tissue in one. RESULTS: All 3 patients had
unequivocal clinical and histopathologic evidence of PXE. No patient (or family
member available for screening) had evidence of mutations in ABCC6. Neither liver
specimen nor the single available kidney specimen showed evidence of mutations in
ABCC6. LIMITATIONS: Liver tissue was not available from one patient and DNA was
of poor quality in another, resulting in limited screening. Genetic testing does not
detect ABCC6 mutations in 10% of patients with confirmed PXE. CONCLUSION:
Although we were unable to demonstrate ABCC6 mutations in limited screening of
fixed donor livers, the absence of any PXE mutations in the affected patients, the
timing of onset of PXE, and the known acquisition of other metabolic disorders and



























Publié sur Okina (http://okina.univ-angers.fr)
